v3.25.1
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Collaborative and license agreements      
AbbVie's receivable from Janssen $ 12,477   $ 10,919
AbbVie's payable to Janssen 31,041   31,945
Janssen Biotech Inc. | Collaborative arrangement      
Collaborative and license agreements      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 25 $ 42  
AbbVie's receivable from Janssen 235   237
AbbVie's payable to Janssen 245   $ 282
Janssen Biotech Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 247 283  
Janssen Biotech Inc. | Collaborative arrangement | International      
Collaborative and license agreements      
International - AbbVie's share of profits (included in net revenues) 209 228  
Genentech, Inc. | Collaborative arrangement      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 242 227  
AbbVie's share of development costs (included in R&D) 17 19  
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 10 $ 9